HCV-Target: Hepatitis C Therapeutic Registry And Research Network-A Longitudinal, Observational Study
The purpose of this study is to collect and study information on patients with chronic Hepatitis C Virus (HCV) who are being treated with the protease inhibitors (telaprevir and boceprevir) that have recently been approved by the FDA. This study investigates if and how drugs affect certain types of patients differently; compares length of HCV treatment in different groups of patients; compares ways to manage drug side effects; identifies genetic reasons as to why certain people react differently to study drugs.
Keywordshepatitis c virus, protease inhibitors, telaprevir, boceprevir, side effects
Principal InvestigatorDavid R Nelson, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.